The probe into insider trading continues with authorities looking at a number of funds, including SAC Capital, a source tells CNBC.» Read More
Good morning. Deborah Taft continues in the lead with a portfolio value of $2,582,726.3, up $366,000 Tuesday, from Monday's value of $2,216,726.30. Deborah's gamble on the ever-active CV Therapeutics paid off and secured her lead position. She went all in on Monday with a buy of 300,000 shares of CVTX at $6.75, and it looks like she caught a bottom...
Good morning. Here are the latest names and numbers from Monday's action. Deborah Taft continues in the lead with a portfolio value of $2,216,726.30. Her biggest portfolio gains continue to be in the ever popular Fremont General which she sold out of completely on 3/21. She made $23,062.62 or 1.05% on buying and selling 164,733 shares of Elan Pharma.
Good morning. Deborah Taft stays in the top position with a portfolio value of $2,187,663.68 for a gain of $2,000.00 or 0.09% from Thursday's action. Deborah was all in cash and received $2,000 in bonus bucks and has put the majority of her holdings into Elan Corp. plc (ELN) as of 3/22. (those bonus bucks from the trivia questions do add up!!)
Elan reported a smaller fourth-quarter loss and higher sales Tuesday, citing the expansion of its multiple sclerosis-fighting drug Tysabri as a major factor.
The same rare, but fatal viral infection that forced Biogen Idec and Elan to recall, and recently relaunch, the multiple sclerosis drug, Tysabri, may also be a side effect of Rituxan, also from Biogen Idec and Genentech. In an SEC filing -- not a press release -- and on the FDA website, the companies and the agency disclosed yesterday evening that two people with lupus died after taking Rituxan.